MAT2B and colorectal carcinoma: The authors demonstrated that in CRC AdoMet and its metabolite methylthioadenosine (MTA) inhibited IL-6/STAT3 signaling, reduced MAT2A and MAT2B expression, and upregulated miR-34a/b levels, resulting in increased apoptosis and decreased cell growth, migration, and metastasis [74].